ICH Q2(R2) analytical procedure validation: what changed and how to apply it

Why the revision matters

The former Q2(R1) framework became strongly associated with conventional chromatographic and spectroscopic procedures. Q2(R2) is written to accommodate a wider range of analytical technologies, including multivariate procedures, while keeping the central question unchanged: does the procedure meet its intended purpose?

Begin with intended purpose and performance criteria

The validation protocol should identify the measured quality attribute, the analytical procedure, the reportable result, the relevant performance characteristics, and predefined acceptance criteria. Q14 describes the analytical target profile, or ATP, as a prospective summary of the intended purpose and the performance criteria for the reportable result.

Specificity and selectivity

Demonstrate that identification or quantitation is not materially affected by impurities, degradation products, matrix components, or other likely interferences. Evidence may come from absence-of-interference studies, comparison with an orthogonal procedure, or a justified technology-inherent capability. Stress or aged samples can support a stability-indicating claim when the study design is scientifically relevant.

Accuracy and precision

Accuracy evaluates agreement between the measured result and an accepted reference value. Precision covers variability under specified conditions. Repeatability examines the same operating conditions over a short interval, while intermediate precision considers relevant within-laboratory variation such as days, analysts, equipment, or environmental conditions.

Response, range, DL and QL

Q2(R2) addresses the response relationship and the reportable range rather than treating linearity as a universal requirement for every technology. Detection limit and quantitation limit remain important where the intended purpose requires reliable detection or quantitation at low levels, including many impurity procedures. The selected approach and calculations require scientific justification.

Multivariate procedures

For a multivariate analytical procedure, validation should address the model, calibration and validation sets, reference values, relevant sources of variation, and controls that keep the model suitable during routine use. A correlation coefficient alone cannot demonstrate fitness for purpose.

The Q14 lifecycle connection

Q14 links analytical development knowledge to validation and change management. A minimal approach remains possible, while enhanced approaches can use prior knowledge, risk assessment, parameter understanding, robustness studies, and an analytical procedure control strategy. The extent of revalidation after a change should follow risk and the effect on procedure performance.

Practical implementation priorities

Update validation SOPs and templates to use Q2(R2) terminology and to link acceptance criteria to intended purpose. Document ATPs for new procedures where appropriate. Revisit how protocols address multivariate methods, reportable range, robustness knowledge, transfer, and post-validation changes. Maintain complete, attributable electronic records and audit trails under applicable data-integrity requirements.

Keep validation and investigation separate

Q2(R2) and Q14 address analytical procedure development and validation. They do not replace approved deviation, OOS, OOT, or CAPA procedures. In the U.S. context, FDA OOS guidance and CGMP requirements govern the operational investigation of unexpected laboratory results.

Primary references

• ICH Q2(R2), Validation of Analytical Procedures, Step 4, 1 November 2023
• ICH Q14, Analytical Procedure Development, Step 4, 1 November 2023
• FDA, Investigating Out-of-Specification Test Results for Pharmaceutical Production, May 2022
• 21 CFR Part 11 and applicable data-integrity requirements